PA
TXMD icon

Profund Advisors’s TherapeuticsMD TXMD Stock Holding History

Profund Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-230
Closed -$4K – 1292
2022
Q1 		$4K Sell
230
-34
-13% -$535 ﹤0.01% 1346
2021
Q4 		$5K Sell
264
-469
-64% -$14.1K ﹤0.01% 1375
2021
Q3 		$27K Buy
733
+1
+0.1% +$44 ﹤0.01% 1348
2021
Q2 		$44K Buy
732
+70
+11% +$4.24K ﹤0.01% 1418
2021
Q1 		$44K Buy
662
+179
+37% +$14K ﹤0.01% 1342
2020
Q4 		$29K Buy
483
+65
+16% +$4.44K ﹤0.01% 1185
2020
Q3 		$33K Buy
418
+10
+2% +$797 ﹤0.01% 961
2020
Q2 		$26K Buy
408
+31
+8% +$1.8K ﹤0.01% 937
2020
Q1 		$20K Sell
377
-52
-12% -$5.16K ﹤0.01% 752
2019
Q4 		$52K Buy
429
+104
+32% +$15K ﹤0.01% 1255
2019
Q3 		$59K Sell
325
-53
-14% -$7.47K ﹤0.01% 1271
2019
Q2 		$49K Sell
378
-87
-19% -$15.6K ﹤0.01% 1201
2019
Q1 		$113K Sell
465
-456
-50% -$121K 0.01% 1180
2018
Q4 		$175K Sell
921
-153
-14% -$37.3K 0.01% 1047
2018
Q3 		$352K Buy
+1,074
New +$329K 0.01% 1071

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Profund Advisors's TXMD Position: Q2 2022 in Review

Profund Advisors sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 230 shares — an estimated $4K sold.

Profund Advisors first reported a position in TXMD in Q3 2018 and held it in 15 quarters. The position peaked at $352K in Q3 2018. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

  • Profund Advisors reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
  • Profund Advisors sold 230 TherapeuticsMD shares in Q2 2022, an estimated $4K.
  • Profund Advisors first reported a position in TherapeuticsMD in Q3 2018 and held it in 15 quarters.
  • Profund Advisors's TherapeuticsMD position peaked at $352K in Q3 2018.
  • 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Profund Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.